A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Narcolepsy
Interventions
DRUG

ADX-N05

150 mg once a day for seven days followed by 300 mg once a day for seven days

DRUG

Placebo

Placebo to match ADX-N05 once a day for 2 consecutive weeks

Trial Locations (10)

20815

The Center for Sleep and Wake Disorders, Chevy Chase

29201

SleepMed of South Carolina, Columbia

30342

Neurotrials Research, Inc., Atlanta

Sleep Disorders Center of Georgia, Atlanta

31201

SleepMed of Central Georgia, Macon

33707

Clinical Research Group of St. Petersburg, St. Petersburg

43623

Mercy St. Anne Sleep Disorders Center, Toledo

75231

Sleep Medicine Associates of Texas, Dallas

78731

Future Search Trials of Neurology, Austin

85006

Pulmonary Associates, Phoenix

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY